1-12 of 12
L White
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis

Open Access
Jia Hu, Meera R. Hameed, Narasimhan P. Agaram, Karissa A. Whiting, Li-Xuan Qin, Anthony M. Villano, Rachael B. O'Connor, Julian M. Rozenberg, Sonia Cohen, Katherine Prendergast, Sara Kryeziu, Richard L. White, Jr, Mitchell C. Posner, Nicholas D. Socci, Mrinal M. Gounder, Samuel Singer, Aimee M. Crago
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 450–461.
https://doi.org/10.1158/1078-0432.CCR-23-2313
Published: 17 January 2024
View articletitled, PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Open the PDF for PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis in another window
Includes: Supplementary data
Journal Articles

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Free
Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5034–5043.
https://doi.org/10.1158/1078-0432.CCR-16-3016
Published: 31 August 2017
View articletitled, Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)
Open the PDF for Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) in another window
Includes: Supplementary data
Journal Articles

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

Free
Kevin J. Harrington, Eleni M. Karapanagiotou, Victoria Roulstone, Katie R. Twigger, Christine L. White, Laura Vidal, Debbie Beirne, Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev S. Pandha, Johann S. DeBono, Alan A. Melcher
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3067–3077.
https://doi.org/10.1158/1078-0432.CCR-10-0054
Published: 31 May 2010
View articletitled, Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Open the PDF for Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

Inherited Determinants of Ovarian Cancer Survival

Free
Ellen L. Goode, Matthew J. Maurer, Thomas A. Sellers, Catherine M. Phelan, Kimberly R. Kalli, Brooke L. Fridley, Robert A. Vierkant, Sebastian M. Armasu, Kristin L. White, Gary L. Keeney, William A. Cliby, David N. Rider, Linda E. Kelemen, Monica B. Jones, Prema P. Peethambaram, Johnathan M. Lancaster, Janet E. Olson, Joellen M. Schildkraut, Julie M. Cunningham, Lynn C. Hartmann
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 995–1007.
https://doi.org/10.1158/1078-0432.CCR-09-2553
Published: 01 February 2010
View articletitled, Inherited Determinants of Ovarian Cancer Survival
Open the PDF for Inherited Determinants of Ovarian Cancer Survival in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

Free
Laura Vidal, Hardev S. Pandha, Timothy A. Yap, Christine L. White, Katie Twigger, Richard G. Vile, Alan Melcher, Matt Coffey, Kevin J. Harrington, Johann S. DeBono
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7127–7137.
https://doi.org/10.1158/1078-0432.CCR-08-0524
Published: 03 November 2008
View articletitled, A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Open the PDF for A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer in another window
Journal Articles

Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy

Free
Mohan Hingorani, Christine L. White, Shane Zaidi, Andrew Merron, Inge Peerlinck, Martin E. Gore, Christopher M. Nutting, Hardev S. Pandha, Alan A. Melcher, Richard G. Vile, Georges Vassaux, Kevin J. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15): 4915–4924.
https://doi.org/10.1158/1078-0432.CCR-07-4049
Published: 01 August 2008
View articletitled, Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy
Open the PDF for Radiation-Mediated Up-Regulation of Gene Expression from Replication-Defective Adenoviral Vectors: Implications for Sodium Iodide Symporter Gene Therapy in another window
Includes: Supplementary data
Journal Articles

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

Free
Devendra K. Hiwase, Verity Saunders, Duncan Hewett, Amity Frede, Stephanie Zrim, Phuong Dang, Laura Eadie, L. Bik To, Junia Melo, Sharad Kumar, Timothy P. Hughes, Deborah L. White
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3881–3888.
https://doi.org/10.1158/1078-0432.CCR-07-5095
Published: 16 June 2008
View articletitled, Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Open the PDF for Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications in another window
Journal Articles

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

Free
Katie Twigger, Laura Vidal, Christine L. White, Johann S. De Bono, Shreerang Bhide, Matt Coffey, Brad Thompson, Richard G. Vile, Lucy Heinemann, Hardev S. Pandha, Fiona Errington, Alan A. Melcher, Kevin J. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 912–923.
https://doi.org/10.1158/1078-0432.CCR-07-1400
Published: 01 February 2008
View articletitled, Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy
Open the PDF for Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy in another window
Includes: Supplementary data
Journal Articles

OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms

Free
Shuhong Zhang, Attaya Suvannasankha, Colin D. Crean, Valerie L. White, Amy Johnson, Ching-Shih Chen, Sherif S. Farag
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4750–4758.
https://doi.org/10.1158/1078-0432.CCR-07-0136
Published: 15 August 2007
View articletitled, OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms
Open the PDF for OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms in another window
Journal Articles

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

Free
Johann S. de Bono, Anthony W. Tolcher, Andre Forero, Gertrude F. A. Vanhove, Chris Takimoto, Robert J. Bauer, Lisa A. Hammond, Amita Patnaik, Mark L. White, Sui Shen, Muhammad B. Khazaeli, Eric K. Rowinsky, Albert F. LoBuglio
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7555–7565.
https://doi.org/10.1158/1078-0432.CCR-04-0729
Published: 29 November 2004
View articletitled, ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas
Open the PDF for ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas in another window
Journal Articles

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

Free
S G Eckhardt, S D Baker, J R Eckardt, T G Burke, D L Warner, J G Kuhn, G Rodriguez, S Fields, A Thurman, L Smith, M L Rothenberg, L White, P Wissel, R Kunka, S DePee, D Littlefield, H A Burris, D D Von Hoff, E K Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (1998) 4 (3): 595–604.
Published: 01 March 1998
View articletitled, Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Open the PDF for Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. in another window
Journal Articles

A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer.

Free
J D Bitran, B L Samuels, S Marsik, A Gambino, L White
Journal: Clinical Cancer Research
Clin Cancer Res (1995) 1 (2): 185–188.
Published: 01 February 1995
View articletitled, A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer.
Open the PDF for A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. in another window